Document is current

Article History

Received: 6 May 2025

Accepted: 12 August 2025

First Online: 26 September 2025

Declarations

:

: Using the Department of Health and Human Services regulations found at 45 CFR 46.104(d)(4), the central IRB (Advarra IRB, Advarra, 6100 Merriweather Drive, Suite 600, Columbia, Maryland, USA) determined that the research project was exempt from the IRB oversight. Individual identifying information was not accessed by the investigators during the study, therefore consent was not required.

: Not applicable.

: PS is a consultant for Gilead Sciences, ViiV Healthcare, and Merck. He received research grants from Gilead Sciences, Merck, and ViiV Healthcare. JR is an employee of Trio Health. MD, NPM and JG are employees of Gilead Sciences. SS serves on the Medical Advisory Board for Gilead Sciences and is a Speaker for Gilead Sciences. KM advises for ViiV Healthcare, Merck, and Gilead Sciences. He is on the speakers’ bureau for ViiV Healthcare, Merck, and Gilead Sciences. He received research grants from ViiV Healthcare, Merck, and Gilead Sciences. MR is a consultant for ViiV Healthcare, Gilead Sciences, and Merck and received research funding from these companies. RE has received grants from Gilead Sciences and ViiV Healthcare, serves on the Advisory boards for Gilead Sciences and ViiV Healthcare, and is a speaker for Gilead Sciences. He is the Chairman of Trio Health Scientific Steering Committee.